European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis
- PMID: 21216817
- DOI: 10.1136/ard.2010.139105
European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis
Abstract
Objectives: To agree terminology and to develop recommendations for the diagnosis of calcium pyrophosphate deposition (CPPD).
Methods: The European League Against Rheumatism (EULAR) CPPD Task Force, comprising 15 experts from 10 countries, agreed the terms and recommendations for diagnosis of CPPD using a Delphi consensus approach. Evidence was systematically reviewed and presented in terms of sensitivity, specificity and positive likelihood ratio (LR) to support diagnosis; ORs were used for association. Strength of recommendation (SOR) was assessed by the EULAR visual analogue scale.
Results: It was agreed that 'CPPD' should be the umbrella term that includes acute calcium pyrophosphate (CPP) crystal arthritis, osteoarthritis (OA) with CPPD and chronic CPP crystal inflammatory arthritis. Chondrocalcinosis (CC) defines cartilage calcification, most commonly due to CPPD and detected by imaging or histological examination. A total of 11 key recommendations were generated on the topics of clinical features, synovial fluid (SF) examination, imaging, comorbidities and risk factors. Definitive diagnosis of CPPD relies on identification of SF CPP crystals. Rapid onset inflammatory symptoms and signs are suggestive but not definitive for acute CPP crystal arthritis. Radiographic CC is not highly sensitive or specific, whereas ultrasonography appears more useful (LR=24.2, 95% CI 3.51 to 168.01) for peripheral joints. Recognised risk factors for CPPD include ageing, OA and metabolic conditions such as primary hyperparathyroidism, haemochromatosis and hypomagnesaemia; familial forms are rare. SORs varied from 53 to 99 (maximum 100).
Conclusion: New terms for CPPD were agreed and 11 key recommendations for diagnosis of CPPD were developed using research evidence and expert consensus.
Similar articles
-
[Pseudogout (Articular chondrocalcinosis) (author's transl)].Ryumachi. 1980 Nov;20(5):383-90. Ryumachi. 1980. PMID: 7048576 Review. Japanese. No abstract available.
-
EULAR recommendations for calcium pyrophosphate deposition. Part II: management.Ann Rheum Dis. 2011 Apr;70(4):571-5. doi: 10.1136/ard.2010.139360. Epub 2011 Jan 20. Ann Rheum Dis. 2011. PMID: 21257614
-
[From chondrocalcinosis to rheumatism with calcium pyrophosphate dehydrate].Rev Prat. 2015 May;65(5):677, 679-80, 682. Rev Prat. 2015. PMID: 26165108 Review. French.
-
Articular chondrocalcinosis in Saudi Arabia.Saudi Med J. 2002 May;23(5):577-9. Saudi Med J. 2002. PMID: 12070585
-
Genetics and mechanisms of crystal deposition in calcium pyrophosphate deposition disease.Curr Rheumatol Rep. 2012 Apr;14(2):155-60. doi: 10.1007/s11926-011-0230-6. Curr Rheumatol Rep. 2012. PMID: 22198832 Review.
Cited by
-
Efficacy of a single ultrasound-guided injection of high molecular weight hyaluronic acid combined with collagen tripeptide in patients with knee osteoarthritis and chondrocalcinosis.Front Med (Lausanne). 2024 Jul 19;11:1437160. doi: 10.3389/fmed.2024.1437160. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39099592 Free PMC article.
-
Calcium Pyrophosphate Crystal Formation and Deposition: Where Do we Stand and What Does the Future hold?Curr Rheumatol Rep. 2024 Oct;26(10):354-365. doi: 10.1007/s11926-024-01161-w. Epub 2024 Aug 1. Curr Rheumatol Rep. 2024. PMID: 39088093 Free PMC article. Review.
-
A Narrative Review of Chondrocalcinosis: Clinical Presentation, Diagnosis, and Therapies.Cureus. 2024 May 16;16(5):e60434. doi: 10.7759/cureus.60434. eCollection 2024 May. Cureus. 2024. PMID: 38882993 Free PMC article. Review.
-
Diastolic Dysfunction of the Left and Right Ventricles in Patients with Calcium Pyrophosphate Crystal Storage Disease and Osteoarthritis.Dokl Biochem Biophys. 2024 Aug;517(1):148-155. doi: 10.1134/S1607672924700881. Epub 2024 Jun 10. Dokl Biochem Biophys. 2024. PMID: 38861149
-
The translational value of calcium pyrophosphate deposition disease experimental mouse models.Front Med (Lausanne). 2024 May 23;11:1417318. doi: 10.3389/fmed.2024.1417318. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38846138 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources